Insmed (INSM) said Friday said it expects to report full-year 2024 global net product sales of its drug Arikayce of $363.7 million, up 19% year over year.
The results are preliminary and subject to adjustment, the company said. Insmed expects to report its actual results in late February.
Analysts polled by FactSet expect $356.8 million in full-year revenue.
Price: 65.21, Change: -0.51, Percent Change: -0.78